Hannah Schwarzschild Attorney | Plaintiffs' Lawyer

Hannah has litigated cases involving employee and consumer rights, and now focuses on antitrust claims in the pharmaceutical industry.

Current Role

Of Counsel, Hagens Berman Sobol Shapiro LLP
Practice focuses on consumer and antitrust cases
Involved in multi-district antitrust litigation involving brand pharmaceutical products, including Zetia, Niaspan and Suboxone, among others.

Experience

Prior to joining Hagens Berman, Ms. Schwarzschild coordinated large-scale litigation projects in Boston and Philadelphia. Over the past 25 years, she has litigated employment and consumer rights cases in federal and state courts and administrative agencies, including jury and bench trials and appeals.

Publications

"Same-Sex Marriage and Constitutional Privacy", Berkeley Women’s Law Journal, 1989

Personal Insight

Hannah grew up in and around New York City. Before law school, she helped build a community arts facility in San Francisco’s Mission District in the 1980s and worked on nuclear arms control at the Ploughshares Fund. Hannah has been working for LGBT rights and Middle East peace and justice for more than 20 years. She loves noodling around cities and beach towns in search of interesting food, art, wildlife and humans.

Related Cases

CASES IN THE NEWS

All Cases

Suboxone Antitrust

Hagens Berman filed a class action alleging that Reckitt Benckiser Pharmaceuticals had violated federal antitrust laws by engaging in a scheme to delay generic competition for its opioid addiction medicine, Suboxone.

Tracleer

Hagens Berman represents plaintiffs in this class-action lawsuit alleging that defendants engaged in a scheme to prolong their monopoly over brand name drug Tracleer.

Niaspan Antitrust

Hagens Berman filed a class action alleging that the 2005 settlement of a patent infringement lawsuit between Kos Pharmaceuticals and Barr Laboratories was a “pay-for-delay” agreement.

Zetia Antitrust

Hagens Berman filed a class action against Merck and Glenmark alleging the two colluded to illegally delay the market entry of generic versions of Merck's cholesterol drug, Zetia.